IMR Press / FBS / Volume 7 / Issue 2 / DOI: 10.2741/S437

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Twenty years of modelling NPM-ALK-induced lymphomagenesis
Show Less
1 Inserm, UMR1037 CRCT, F-31000 Toulouse, France
2 Université Toulouse III-Paul Sabatier, UMR1037 CRCT, F-31000 Toulouse, France
3 CNRS, ERL5294 CRCT, F-31000 Toulouse, France
4 Division of Molecular Histopathology, Department of Pathology, Lab Block Level 3, Box 231, Addenbrooke’s Hospital, Cambridge CB20QQ
5 European Research Initiative on ALK-related malignancies (ERIA)

*Author to whom correspondence should be addressed.

Academic Editor: Roberto Chiarle

Front. Biosci. (Schol Ed) 2015, 7(2), 236–247;
Published: 1 June 2015
(This article belongs to the Special Issue ALK: 20 years of discoveries)

Our current understanding of oncogenic Anaplastic Lymphoma Kinase (ALK)-induced lymphomagenesis has relied for over 20 years on multiple and complementary studies performed on various experimental models, encompassing ALK oncogene expressing cells, their grafts into immune-compromised mice, the generation of genetically engineered mouse models (GEMMs) and, when available, the use of patient samples from Anaplastic Large Cell Lymphoma (ALCL) tumour banks. Of note, and to our knowledge, no ALK-positive ALCL 3D culture system has been described so far. In this review, we will first outline how these different cell and mouse models were designed, and what key findings they revealed (or confirmed) towards oncogenic ALK-induced lymphomagenesis. Secondly, we will discuss how recent and revolutionary advances in genetic engineering technology are likely to complete our understanding of ALK-related diseases in an effort to improve current therapeutic approaches.

Mouse models
Cancer models
In vitro cancer models
Back to top